|
Eli
Lilly and Company, a world leader in diabetes care for more than 75
years, has developed more than 40 insulin products. More than 10 million
individuals with diabetes around the world rely on insulin. People with
type 1 diabetes always require insulin; as many as 58% of people with
type 2 diabetes will need insulin as their disease progresses.¹
In New
Zealand, Lilly provides the Humulin range of
human insulins, along with more advanced insulins such as Humalog, a
rapid-acting insulin analogue, the first of its kind to be made
available. Lilly also provides the easy-to-use HumaPen
for use with our 3ml Humulin and Humalog cartridges, making insulin injections truly
easy. The HumaPen includes many easy-to-use
design features not currently available in other insulin pens. For more
information about our Humulin or Humalog insulin ranges or about Lilly's HumaPen, call us on 0800-500-909 or ask your diabetes
health professional.
Lilly
is also involved in numerous support activities in New Zealand for
diabetes healthcare professionals and for people with diabetes. Some of
these activities include
- Lilly Diabetes Research Grant
- Lilly Diabetes Educators' Study Day
- Diabetes Industry Association - diabetes nurse
educators' education travel fund
- Regional Medical Conferences
- Sponsorship of NZSSD Annual Scientific meeting
- Lilly Diabetes Youth Awards
- Assistance with Children's Diabetes Camps
- 50 Year Medals - awarded to people who have been using insulin
for more than 50 years
1.
American Diabetes Association, Vital Statistics, 1996.
Humulin (human insulin, rDNA
origin, Lilly), Humalog (insulin lispro, rDNA origin, Lilly)
are restricted medicines only available from pharmacies. Humulin®, Humalog® and HumaPen® are registered trademarks of Eli Lilly and
Company.
|
